@inproceedings{703cb2e612b94e5090e6b35519a19b9f,
title = "Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Paris, France, 20–21 May 2025",
abstract = "Lipodystrophy syndromes are rare diseases characterized by anatomical and functional defects of adipose tissue, frequently leading to severe insulin resistance-associated metabolic complications. Subtypes of lipodystrophy syndromes differ in: their clinical presentation, with generalized or partial loss of adipose tissue; in their origin, either genetic or acquired; and in their comorbidities, forming a heterogeneous group of disorders of different severity. The European Consortium of Lipodystrophies (ECLip) was founded in 2014 as a non-profit network of health professionals, scientists and patient associations. ECLip aims to promote international collaborations to increase pathophysiological and clinical knowledge, and improve the management of lipodystrophy syndromes. ECLip now comprises 59 groups from 30 countries from Europe and beyond. The consortium developed in parallel to the increased awareness of clinical diagnosis, the growing scientific interest for these diseases at the crossroads between adipose tissue biology, whole body metabolism, genetics and immunity, and to the emergence of new pharmacological approaches. The ECLip congress, held every 18 months, aims to discuss the recent achievements and projects in the field of lipodystrophies, to consolidate ECLip activities and to promote future collaborations, highlighting clinical and fundamental aspects as well as patients{\textquoteright} perspectives. Oral communications presented during the meeting in Paris, France, in 2025 are summarized in these minutes.",
keywords = "Lipodystrophy, Laminopathies, Adipocytes, Cardiovascular disease, Seipin, Mitochondria, Registry, Natural history, Leptin, Quality of life, POLD1, Cellular senescence, Caveolin-1, Therapies, Epidemiology, Auto-immunity, Diet, Lipidomic, Chromatin, Metabolism",
author = "Camille Vatier and David Ara{\'u}jo-Vilar and Baris Akinci and Thierry Arnould and Carine Beaup{\`e}re and Elise Bismuth and Brown, \{Rebecca J.\} and Giovanni Ceccarini and Philippe Collas and Alessandra Gambineri and Donatella Gilio and Sharon Halperin and Sonja Janmaat and Sophie Lamothe and Giovanna Lattanzi and Margherita Maffei and MacDougald, \{Ormond A.\} and H{\'e}l{\'e}na Mosbah and Estelle Nobecourt and Oral, \{Elif A.\} and Justin Rochford and Ferruccio Santini and Schirmer, \{Eric C.\} and \{von Schnurbein\}, Julia and Robert Semple and Daniel Tews and Martin Wabitsch and Marie-Christine Vantyghem and Corinne Vigouroux",
note = "The ECLip meeting Paris 2025 was endorsed by the European Reference Network for Rare Endocrine Conditions Endo-ERN, the French Endocrine Society (Soci{\'e}t{\'e} Fran{\c c}aise d{\textquoteright}Endocrinologie, SFE), the Francophone Diabetes Society (Soci{\'e}t{\'e} Francophone du Diab{\`e}te [SFD]), and the French National Healthcare Network for Rare Endocrine Diseases (Fili{\`e}re des Maladies Rares Endocriniennes [FIRENDO]). The authors thank the Robert Debr{\'e} Association for Medical Research (Association Robert Debr{\'e} pour la Recherche M{\'e}dicale [ARDRM]) for management support, and all the participants to the meeting for their stimulative contributions. The ECLip members are very grateful to Chiesi Farmaceutici, Regeneron Pharmaceuticals, Lilly, AstraZeneca, Medison, Novo Nordisk, Sanofi, Timkl, for their financial support, without any role in the preparation and conduction of the meeting, unless the sponsoring of two communications as mentioned in the abstracts. The authors thank the editor-in-chief Prof. Fr{\'e}d{\'e}ric Castinetti for his support in the publication of ECLip meetings proceedings.",
year = "2025",
month = sep,
doi = "10.1016/j.ando.2025.102432",
language = "English",
volume = "86",
series = "Annales d'Endocrinologie",
publisher = "Elsevier",
booktitle = "Annales d'Endocrinologie",
address = "Netherlands",
edition = "5",
}